BofA Securities analyst Jason Gerberry downgraded LENZ Therapeutics Inc (NASDAQ: LENZ) from Buy to Neutral with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades